Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
67%(2 trials)

Phase Distribution

Ph early_phase_1
1
20%
Ph phase_4
1
20%
Ph phase_2
1
20%
Ph phase_1
1
20%

Phase Distribution

2

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution4 total trials
Early Phase 1First-in-human
1(25.0%)
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
1(25.0%)
Phase 4Post-market surveillance
1(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(3)
Terminated(1)
Other(1)

Detailed Status

Completed3
unknown1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (25.0%)
Phase 11 (25.0%)
Phase 21 (25.0%)
Phase 41 (25.0%)

Trials by Status

unknown120%
withdrawn120%
completed360%

Recent Activity

0 active trials
Showing 5 of 5
completed

The Impact of the Human Papilloma Virus in Pediatric Chronic Kidney Disease, Dialysis, and Transplant Patients

NCT00767897
completedphase_2

Randomized, Double Blind Trial of the Quadrivalent HPV Vaccine to Improve Responses to LEEP Treatment of Cervical HSIL

NCT01928225
unknownphase_1

A Controlled Study to Evaluate the Safety and Immunogenicity of StreptAnova™ in Healthy Adults

NCT02564237
withdrawnearly_phase_1

Therapeutic Treatment With Human Papillomavirus Quadrivalent Vaccine for Recurrent Respiratory Papillomatosis

NCT00829608
completedphase_4

Immune Response to the Human Papillomavirus Vaccine in Young Women With Inflammatory Bowel Disease

NCT01034358

Clinical Trials (5)

Showing 5 of 5 trials
NCT00767897

The Impact of the Human Papilloma Virus in Pediatric Chronic Kidney Disease, Dialysis, and Transplant Patients

Completed
NCT01928225Phase 2

Randomized, Double Blind Trial of the Quadrivalent HPV Vaccine to Improve Responses to LEEP Treatment of Cervical HSIL

Completed
NCT02564237Phase 1

A Controlled Study to Evaluate the Safety and Immunogenicity of StreptAnova™ in Healthy Adults

Unknown
NCT00829608Early Phase 1

Therapeutic Treatment With Human Papillomavirus Quadrivalent Vaccine for Recurrent Respiratory Papillomatosis

Withdrawn
NCT01034358Phase 4

Immune Response to the Human Papillomavirus Vaccine in Young Women With Inflammatory Bowel Disease

Completed

All 5 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
5